Galmed Pharmaceuticals's total assets for Q3 2025 were $21.58M, a decrease of -5.93% from the previous quarter. GLMD total liabilities were $2.47M for the fiscal quarter, a 2.11% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.